By Charlotte Plestant (Scientific Content Manager), Shanyate Simonin (QARA Manager) - 31 Aug 2021
Life Science industry is among the most heavily regulated industries in the world. This regulatory environment is continuously changing in response to the introduction of new technologies, the increasing complexity of disease targets and the rising demands of both patients and regulators. We caught up with our QARA Manager Shanyate Simonin to discuss how Keen Eye deploys innovative deep learning technology within such a regulated industry.
10 Aug 2021
Cervical cancer is the second most important cancer for women worldwide. The method uses deep convolutional neural networks. The method avoids medically critical mistakes using regression constraint in the loss term. The method uses interpretability to perform weakly supervised localisation. The method is integrated in a workflow that matches pathologist workflow. The method proposes to aggregate tile-level predictions to output a slide-level diagnosis.
By Charlotte Plestant, Louis Jeay, Suliman Bouizaguen, David Guet - 26 Jul 2021
Delivering the right treatment to the right patient, and at the right time. This motto has become the driving force in drug development, placing solutions empowering personalized medicine as a top priority in the Pathology field. The scientific community is striving to answer the technological needs required by such a challenge. Multiplex fluorescence IHC (immunohistochemistry) is a revolutionary method offering powerful possibilities in simultaneous analysis of multiple biomarkers on whole tissue sections. In this post, we describe why understanding spatial biology, the study of tissues in their 2D and 3D context, is the next big step the field has to take and how Deep Learning will assist in unraveling personalized medicine.
By Charlotte Plestant (Scientific Content Marketing Manager), Eunice Stennett (Former CMO), David Guet (Digital pathology Specialist) - 26 May 2021
Over the last years, the world of Pathology has considerably evolved and brought out new challenges. Development of whole-slide scanners alongside Artificial Intelligence (AI) has empowered pathological analysis by digitizing immunohistochemistry, immunocytochemistry and H&E slides, providing better possibilities in patient selection and treatment. These changes have come with new hurdles, related to a sharp increase of the complexity of the images, higher expectations for image analysis and a shift in the pathologist's daily practices.
By Sylvain Berlemont (CEO), Shazia Osman (Senior BD), Kevin Adam (Senior BD) - 02 Apr 2021
Keen Eye is attending the Biomarker Series Week starting May 17th to the 21st! Our CEO, Sylvain Berlemont will introduce Keen Eye in a Thought Leader presentation and our business team will be happy to meet you to discuss about your biomarker research and analysis projects.